المؤلفون: Brugières, Laurence, Cozic, Nathalie, Houot, Roch, Rigaud, Charlotte, Sibon, David, Arfi-Rouche, Julia, Bories, Pierre, Cottereau, Anne S, Delmer, Alain, Ducassou, Stéphane, Garnier, Nathalie, Lamant, Laurence, Leruste, Amaury, Millot, Frédéric, Moalla, S., Morschhauser, Franck, Nolla, Marie, Pagnier, Anne, Reguerre, Yves, Renaud, Loïc, Schmitt, Anne, Simonin, Mathieu, Verschuur, Arnaud, Labouret, Nathalie Hoog, Mahier Ait-Oukhatar, Celine, Vassal, Gilles

المساهمون: AP-HP. Université Paris Saclay, Institut Gustave Roussy (IGR), Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique Gustave Roussy, Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Université de Rennes (UR), CHU Henri Mondor Créteil, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Cochin Broca Hôtel Dieu Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Hôpital universitaire Robert Debré Reims (CHU Reims), Université de Reims Champagne-Ardenne (URCA), Centre Hospitalier Universitaire de Bordeaux (CHU de Bordeaux), Institut d'hématologie et d'oncologie pédiatrique CHU - HCL (IHOPe), Hospices Civils de Lyon (HCL), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Curie Paris, Université Paris Sciences et Lettres (PSL), CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402), Université de Poitiers = University of Poitiers (UP)-Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie )-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Hopital Saint-Louis AP-HP (AP-HP), Université Paris-Sud - Paris 11 (UP11), Institut Bergonié Bordeaux, UNICANCER, CHU Trousseau APHP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Hôpital de la Timone CHU - APHM (TIMONE), Institut national du cancer (INCa), This programme was founded by the INCa, the ARC Foundation for Cancer Research, and Unicancer’s personalised medicine research partners. This work was institutionally supported by Pfizer. No grant number is applicable.

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-04228222Test ; European Journal of Cancer, 2023, 191, pp.112984. ⟨10.1016/j.ejca.2023.112984⟩.

مصطلحات موضوعية: Anaplastic large-cell lymphoma ALK plus, Crizotinib, ALK inhibitors, MESH: Adolescent, MESH: Adult, MESH: Protein-Tyrosine Kinases / therapeutic use, MESH: Proto-Oncogene Proteins, MESH: Receptor Protein-Tyrosine Kinases / therapeutic use, MESH: Young Adult, MESH: Anaplastic Lymphoma Kinase, MESH: Child, MESH: Crizotinib / therapeutic use, MESH: Humans, MESH: Lung Neoplasms* / drug therapy, MESH: Lymphoma, Large-Cell, Anaplastic* / drug therapy, MESH: Neoplasm Recurrence, Local / drug therapy, MESH: Protein Kinase Inhibitors / adverse effects, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37549532; hal-04228222; https://hal.science/hal-04228222Test; https://hal.science/hal-04228222/documentTest; https://hal.science/hal-04228222/file/2023_Cozic_EurJCancer.pdfTest; PUBMED: 37549532

الإتاحة: https://doi.org/10.1016/j.ejca.2023.112984Test
https://hal.science/hal-04228222Test
https://hal.science/hal-04228222/documentTest
https://hal.science/hal-04228222/file/2023_Cozic_EurJCancer.pdfTest

المؤلفون: Hansen, Karin Holmskov, Johansen, Jakob Sidenius, Urbanska, Edyta Maria, Meldgaard, Peter, Hjorth-Hansen, Peter, Kristiansen, Charlotte, Stelmach, Miroslaw, Santoni-Rugiu, Eric, Ulhøi, Maiken Parm, Dydensborg, Anders Bondo, Dünweber, Christina, Andersen, Jon Lykkegaard

المصدر: Hansen , K H , Johansen , J S , Urbanska , E M , Meldgaard , P , Hjorth-Hansen , P , Kristiansen , C , Stelmach , M , Santoni-Rugiu , E , Ulhøi , M P , Dydensborg , A B , Dünweber , C & Andersen , J L 2023 , ' Clinical outcomes of ALK+ non-small cell lung cancer in Denmark ' , Acta oncologica (Stockholm, Sweden) , vol. 62 , no. 12 , pp. 1775-1783 . https://doi.org/10.1080/0284186X.2023.2263153Test

مصطلحات موضوعية: ALK+non-small cell lung cancer, clinical outcome, nationwide, prevalence, retrospective, treatment use and duration, Humans, Middle Aged, Anaplastic Lymphoma Kinase/antagonists & inhibitors, Crizotinib/therapeutic use, Denmark/epidemiology, Lung Neoplasms/drug therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Protein Kinase Inhibitors/therapeutic use, Female, Retrospective Studies

العلاقة: https://pure.au.dk/portal/en/publications/794df66a-6109-48b0-a085-e2c6ede6ce5fTest

الإتاحة: https://doi.org/10.1080/0284186X.2023.2263153Test
https://pure.au.dk/portal/en/publications/794df66a-6109-48b0-a085-e2c6ede6ce5fTest

المساهمون: D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario Garcia Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I Spira, Scott N Gettinger, Marcello Tiseo, Huamao M Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat, Kim, Hye Ryun

مصطلحات موضوعية: Anaplastic Lymphoma Kinase / genetics, Crizotinib / therapeutic use, Humans, Lung Neoplasms* / drug therapy, Lung Neoplasms* / genetics, Organophosphorus Compounds, Protein Kinase Inhibitors / therapeutic use, Pyrimidines / therapeutic use, ALK tyrosine kinase inhibitor, Anaplastic lymphoma kinase, Brigatinib, Crizotinib, Non–small cell lung cancer

العلاقة: JOURNAL OF THORACIC ONCOLOGY; J01909; OAK-2022-04520; https://ir.ymlib.yonsei.ac.kr/handle/22282913/190628Test; T202126214; JOURNAL OF THORACIC ONCOLOGY, Vol.16(12) : 2091-2108, 2021-12

الإتاحة: https://doi.org/10.1016/j.jtho.2021.07.035Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190628Test

المساهمون: D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander Spira, Scott N Gettinger, Marcello Tiseo, Huamao M Lin, Neeraj Gupta, Michael J Hanley, Quanhong Ni, Pingkuan Zhang, Sanjay Popat, Kim, Hye Ryun

مصطلحات موضوعية: Adolescent, Adult, Aged, Anaplastic Lymphoma Kinase / antagonists & inhibitors, Anaplastic Lymphoma Kinase / metabolism, Antineoplastic Agents / adverse effects, Antineoplastic Agents / blood, Antineoplastic Agents / pharmacokinetics, Antineoplastic Agents / therapeutic use, Carcinoma, Non-Small-Cell Lung / drug therapy, Non-Small-Cell Lung / metabolism, Crizotinib / adverse effects, Crizotinib / blood, Crizotinib / pharmacokinetics, Crizotinib / therapeutic use, Female, Humans, Lung Neoplasms / drug therapy, Lung Neoplasms / metabolism, Male, Middle Aged, Organophosphorus Compounds / adverse effects, Organophosphorus Compounds / blood, Organophosphorus Compounds / pharmacokinetics, Organophosphorus Compounds / therapeutic use, Progression-Free Survival, Pyrimidines / adverse effects, Pyrimidines / blood, Pyrimidines / pharmacokinetics

العلاقة: JOURNAL OF CLINICAL ONCOLOGY; J01331; OAK-2021-02400; https://ir.ymlib.yonsei.ac.kr/handle/22282913/183815Test; T202007102; JOURNAL OF CLINICAL ONCOLOGY, Vol.38(31) : 3592-3603, 2020-11

الإتاحة: https://doi.org/10.1200/JCO.20.00505Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/183815Test

المساهمون: D.R. Camidge, H.R. Kim, M.-J. Ahn, J.C.-H. Yang, J.-Y. Han, J.-S. Lee, M.J. Hochmair, J.Y.-C. Li, G.-C. Chang, K.H. Lee, C. Gridelli, A. Delmonte, R. Garcia Campelo, D.-W. Kim, A. Bearz, F. Griesinger, A. Morabito, E. Felip, R. Califano, S. Ghosh, A. Spira, S.N. Gettinger, M. Tiseo, N. Gupta, J. Haney, D. Kerstein, S. Popat, Kim, Hye Ryun

مصطلحات موضوعية: Adult, Aged, 80 and over, Anaplastic Lymphoma Kinase/analysis, Anaplastic Lymphoma Kinase/antagonists & inhibitors, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Brain Neoplasms/secondary, Carcinoma, Non-Small-Cell Lung/chemistry, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/secondary, Crizotinib/adverse effects, Crizotinib/therapeutic use, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms/chemistry, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Male, Middle Aged, Organophosphorus Compounds/adverse effects, Organophosphorus Compounds/therapeutic use, Progression-Free Survival, Pyrimidines/adverse effects, Pyrimidines/therapeutic use

العلاقة: New England Journal of Medicine; J02371; OAK-2019-02763; https://ir.ymlib.yonsei.ac.kr/handle/22282913/170865Test; T201806074; New England Journal of Medicine, Vol.379(21) : 2027-2039, 2018

الإتاحة: https://doi.org/10.1056/NEJMoa1810171Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/170865Test

المؤلفون: Dziadziuszko, R., Peters, S., Ruf, T., Cardona, A., Guerini, E., Kurtsikidze, N., Smoljanovic, V., Planchard, D.

المصدر: ESMO open, vol. 7, no. 6, pp. 100612

مصطلحات موضوعية: Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/pathology, Crizotinib/therapeutic use, Lung Neoplasms/pathology, Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors/adverse effects, Receptor Protein-Tyrosine Kinases/therapeutic use, ALK-positive NSCLC, alectinib, clinical experience, safety, tolerability

وصف الملف: application/pdf

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36375271; info:eu-repo/semantics/altIdentifier/eissn/2059-7029; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6AC5881EE42A2; https://serval.unil.ch/notice/serval:BIB_6AC5881EE42ATest; urn:issn:2059-7029; https://serval.unil.ch/resource/serval:BIB_6AC5881EE42A.P001/REF.pdfTest; http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_6AC5881EE42A2Test

الإتاحة: https://doi.org/10.1016/j.esmoop.2022.100612Test
https://serval.unil.ch/notice/serval:BIB_6AC5881EE42ATest
https://serval.unil.ch/resource/serval:BIB_6AC5881EE42A.P001/REF.pdfTest
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_6AC5881EE42A2Test

المؤلفون: Jensen, Kristian H, Persson, Gitte, Storgaard, Lone, Nielsen, Birgitte B, Pedersen, Berit W, Maroun, Lisa L, Huitema, Alwin, Pøhl, Mette

المصدر: Acta Oncologica, 58(1), 121. Informa Healthcare

مصطلحات موضوعية: Adult, Letter, HELLP Syndrome/etiology, Antineoplastic Agents/therapeutic use, Hematology, Case Reports, Pregnancy Complications, Neoplastic/drug therapy, Crizotinib/therapeutic use, respiratory tract diseases, Fatal Outcome, Oncology, Pregnancy, Radiology Nuclear Medicine and imaging, hemic and lymphatic diseases, Humans, Female, Lung Neoplasms/drug therapy, Adenocarcinoma of Lung/drug therapy

وصف الملف: text/plain

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=narcis______::468440f47d8e7449828d960a8ffd98f4Test
https://dspace.library.uu.nl/handle/1874/394307Test

المؤلفون: Alice T. Shaw, Shirish M. Gadgeel, Solange Peters, S-H.I. Ou, Silvia Novello, Ali Zeaiter, Maurice Pérol, Anna Wrona, D.R. Camidge, Dong Wan Kim, Bogdana Balas, Eveline Nüesch, Ting Liu, Tony Mok, Rafael Rosell

المصدر: Annals of oncology, vol. 29, no. 11, pp. 2214-2222

مصطلحات موضوعية: 0301 basic medicine, Alectinib, Oncology, Male, Adult, Aged, Aged, 80 and over, Anaplastic Lymphoma Kinase/antagonists & inhibitors, Anaplastic Lymphoma Kinase/genetics, Brain/diagnostic imaging, Brain/drug effects, Brain/radiation effects, Brain Neoplasms/diagnostic imaging, Brain Neoplasms/genetics, Brain Neoplasms/secondary, Brain Neoplasms/therapy, Carbazoles/pharmacology, Carbazoles/therapeutic use, Carcinoma, Non-Small-Cell Lung/diagnostic imaging, Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung/secondary, Carcinoma, Non-Small-Cell Lung/therapy, Chemoradiotherapy/methods, Crizotinib/pharmacology, Crizotinib/therapeutic use, Disease Progression, Female, Humans, Lung/diagnostic imaging, Lung/drug effects, Lung/radiation effects, Lung Neoplasms/diagnostic imaging, Lung Neoplasms/genetics, Lung Neoplasms/pathology, Lung Neoplasms/therapy, Magnetic Resonance Imaging, Middle Aged, Piperidines/pharmacology, Piperidines/therapeutic use, Treatment Outcome, Tumor Burden/drug effects, Tumor Burden/radiation effects, Young Adult, Lung Neoplasms, ALK+, medicine.medical_treatment, 0302 clinical medicine, Piperidines, Carcinoma, Non-Small-Cell Lung, Clinical endpoint, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Lung, Brain Neoplasms, Hazard ratio, Brain, Hematology, Chemoradiotherapy, Tumor Burden, 030220 oncology & carcinogenesis, CNS, medicine.drug, medicine.medical_specialty, Carbazoles, 03 medical and health sciences, Crizotinib, Internal medicine, medicine, Carcinoma, Lung cancer, non-small-cell lung cancer, business.industry, medicine.disease, Radiation therapy, 030104 developmental biology, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202d9467b40c9c8632a07affb6261137Test
https://pubmed.ncbi.nlm.nih.gov/30239586Test

المصدر: Acta Oncologica. 58(1):121

مصطلحات موضوعية: Adult, Letter, HELLP Syndrome/etiology, Antineoplastic Agents/therapeutic use, Hematology, Case Reports, Crizotinib/therapeutic use, respiratory tract diseases, Pregnancy Complications, Fatal Outcome, Oncology, Pregnancy, Radiology Nuclear Medicine and imaging, hemic and lymphatic diseases, Neoplastic/drug therapy, Humans, Female, Lung Neoplasms/drug therapy, Adenocarcinoma of Lung/drug therapy

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dris___00893::370191cfa6186ed3abd398e3170cefc6Test
https://doi.org/10.1080/0284186x.2018.1497302Test